David Sallman, MD, Moffitt Cancer Center, Tampa, FL, and Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, discuss key updates in myelodysplastic syndromes (MDS) presented at the 2022 ASH Annual Meeting. In this discussion, Dr Sallman and Dr Brunner first comment on treatment approaches for lowerrisk MDS, including the role of luspatercept and imetelstat, and ongoing clinical trials in this space, including the SINTRAREV trial (NCT01243476) and the IMerge trial (NCT02598661). Following this, Dr Sallman and Dr Brunner discuss treatment options for patients with higherrisk MDS and challenges in this space, as well as the role of novel classification systems. Several clinical trials are also highlighted, including the STIMULUSMDS1 trial (NCT03946670), the VERONA trial (NCT04401748) and the SELECT MDS1 trial (NCT04797780). To conclude, Dr Sallman and Dr Brunner share some insights into treatment approaches for patients with hypomethylating agent (HMA) failure MDS, emphasizing the importance of novel targets and transplant consideration. This discussion took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.